Drugs Made In America Acquisition II names Saleem Elmasri CFO

Rhea-AI Filing Summary

Drugs Made In America Acquisition II Corp. reported that its Chief Financial Officer and principal financial and accounting officer, Glenn Worman, resigned effective October 8, 2025, and stated his resignation was not due to any disagreement with the company’s operations, policies or practices. On November 17, 2025, the company appointed Saleem Elmasri as its new Chief Financial Officer and principal financial and accounting officer, providing his services through a Master Services Agreement with Titan Advisory Services LLC. Under this agreement, Titan Advisory Services LLC will receive $42,000 per year, or $3,500 per month, and Mr. Elmasri will receive 100,000 ordinary shares upon engagement. Mr. Elmasri is a CPA with 20 years of financial and consulting experience, including prior roles at PricewaterhouseCoopers and several advisory firms.

Insights

Corporate governance and SPAC specialist

DMIIU discloses a CFO change with consulting-based compensation and equity grant.

The company reports that former Chief Financial Officer Glenn Worman resigned effective October 8, 2025, and that he indicated his departure was not due to any disagreement with the company’s operations, policies, or practices. This helps frame the change as a routine leadership transition rather than a response to internal disputes.

On November 17, 2025, Saleem Elmasri was appointed Chief Financial Officer and principal financial and accounting officer, providing services through Titan Advisory Services LLC under a Master Services Agreement. The arrangement pays Titan Advisory Services LLC $42,000 per year, or $3,500 per month, and includes a grant or transfer of 100,000 ordinary shares to Mr. Elmasri upon engagement. His background as a CPA with 20 years of experience, including work at PricewaterhouseCoopers and multiple advisory firms, indicates familiarity with complex accounting and transaction work.

The company also notes that Mr. Elmasri is expected to enter into an Indemnity Agreement, Letter Agreement, and Registration Rights Agreement on the same terms as other directors and officers, aligning his contractual framework with existing leadership. There are no disclosed family relationships or related-party transactions under Item 404(a) tied to his appointment, which provides additional clarity around potential conflicts.

false 0002040475 0002040475 2025-10-08 2025-10-08 0002040475 DMIIU:UnitsEachConsistingOfOneOrdinaryShareAndOneRightToReceiveOnetenth110OfOneOrdinaryShareMember 2025-10-08 2025-10-08 0002040475 DMIIU:OrdinarySharesParValue0.0001PerShareMember 2025-10-08 2025-10-08 0002040475 DMIIU:RightsEachEntitlingHolderToReceiveOnetenth110OfOneOrdinaryShareMember 2025-10-08 2025-10-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 8, 2025

Date of Report (Date of earliest event reported)

Drugs Made In America Acquisition II Corp.

(Exact Name of Registrant as Specified in its Charter)

Cayman Islands		001-42863		98-1815624
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1 East Broward Boulevard, Suite 700 Fort Lauderdale, FL		33301
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (954) 870-3099

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Units, each consisting of one Ordinary Share and one Right to receive one-tenth (1/10) of one Ordinary Share		DMIIU		The Nasdaq Stock Market LLC
Ordinary Shares, par value $0.0001 per share		DMII		The Nasdaq Stock Market LLC
Rights, each entitling the holder to receive one-tenth (1/10) of one Ordinary Share		DMIIR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Principal Financial and Accounting Officer

On October 8, 2025, Glenn Worman, the Chief Financial Officer and principal financial and accounting officer of Drugs Made In America Acquisition II Corp. (the “Company”) delivered to the Company a notice of resignation from his position as Chief Financial Officer and principal financial and accounting officer of the Company. Mr. Worman’s resignation is effective October 8, 2025. Mr. Worman indicated that his resignation was not the result of any disagreement with the Company regarding its operations, policies, practices or otherwise.

Appointment of Principal Financial and Accounting Officer

On November 17, 2025, the Company appointed Saleem Elmasri as Chief Financial Officer and principal financial and accounting officer of the Company and entered into a Master Services Agreement (the “Consulting Agreement”) with Titan Advisory Services LLC for the provision of such principal financial and accounting officer services by Mr. Elmasri. Mr. Elmasri’s appointment to principal financial and accounting officer of the Company will be effective beginning November 17, 2025. Under the terms of the Consulting Agreement, the Company will pay Titan Advisory Services LLC $42,000 per year, or $3,500 per month, for services rendered by Mr. Elmasri as Chief Financial Officer. In addition, the Company shall grant, or the Company’s Chief Executive Officer, Lynn Stockwell, shall transfer 100,000 shares of the Company’s ordinary shares to Saleem Elmasri upon engagement.

Mr. Elmasri’s biographical information is as follows:

Mr. Elmasri is a CPA and seasoned business professional with 20 years of experience in financial and management consulting. Mr. Elmasri began his career at PricewaterhouseCoopers(“PwC”) and worked on several of the firm’s Fortune 500 clients, primarily focused on the Life Sciences and Pharmaceutical industry. From PwC, he transitioned to lead advisory practices at boutique consulting firms, specializing in transaction and complex accounting advisory.

From September 2020 to the present, he has served as the Managing Partner at Titan Advisory Services LLC, a boutique advisory firm focused on providing collaborative and customized financial operations and CFO services to early-stage companies. From June 2019 to August 2020, he was Managing Director at DLA LLC. From March 2018 to June 2019, he worked as Senior Director for Pine Hill Group LLC, a boutique accounting and transaction advisory firm. From September 2007 to March 2018, Mr. Elmasri advanced through a series of progressively responsible roles, culminating in the position of Senior Manager for PricewaterhouseCoopers LLP, a Big-4 Accounting and Global Professional Services firm. Mr. Elmasri received B.S. degrees in Accounting and Finance from Rutgers University in 2007.

In connection with his appointment, Mr. Elmasri is expected to enter into an Indemnity Agreement, a Letter Agreement and a Registration Rights Agreement with the Company on the same terms as the other directors and officers of the Company that executed similar agreements at the time of the consummation of the Company’s initial public offering. The Indemnity Agreement, Letter Agreement and Registration Rights Agreement will be in the forms of the agreement that are filed as exhibits to the Company’s Annual Report on Form 10-K, which was filed with the U.S. Securities and Exchange Commission. Other than the foregoing, Mr. Elmasri is not party to any arrangement or understanding with any person pursuant to which he was appointed as an executive officer of the Company, nor is he party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving the Company. There are no family relationships between Mr. Elmasri and any of the Company’s directors and executive officers. 

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 17, 2025

DRUGS MADE IN AMERICA ACQUISITION II CORP.
By:	/s/ Lynn Stockwell
Name:	Lynn Stockwell
Title:	Chief Executive Officer

2

FAQ

Why did DMIIU s Chief Financial Officer Glenn Worman resign?

The company states that Glenn Worman resigned as Chief Financial Officer and principal financial and accounting officer effective October 8, 2025, and that he indicated his resignation was not the result of any disagreement with the company regarding its operations, policies, practices or otherwise.

Who is the new CFO of Drugs Made In America Acquisition II Corp. (DMIIU)?

Saleem Elmasri was appointed Chief Financial Officer and principal financial and accounting officer effective November 17, 2025. He is a CPA with 20 years of experience in financial and management consulting, including senior roles at PricewaterhouseCoopers, Pine Hill Group LLC, DLA LLC, and as Managing Partner at Titan Advisory Services LLC.

How is DMIIU compensating its new CFO, Saleem Elmasri?

Under a Master Services Agreement with Titan Advisory Services LLC, the company will pay $42,000 per year, or $3,500 per month, for Mr. Elmasri s services as Chief Financial Officer. In addition, the company will either grant or have its Chief Executive Officer transfer 100,000 ordinary shares to Saleem Elmasri upon engagement.

What prior experience does DMIIU s new CFO, Saleem Elmasri, have?

Saleem Elmasri has 20 years of experience in financial and management consulting. He began his career at PricewaterhouseCoopers, working with Fortune 500 clients in the Life Sciences and Pharmaceutical industry, later holding senior roles at boutique advisory firms including Pine Hill Group LLC and DLA LLC. Since September 2020, he has been Managing Partner at Titan Advisory Services LLC, and he holds B.S. degrees in Accounting and Finance from Rutgers University, earned in 2007.

Are there any related-party transactions or family relationships disclosed for DMIIU s new CFO?

The company states that, other than the compensation and share grant or transfer described, Saleem Elmasri is not party to any arrangement or understanding with any person pursuant to which he was appointed, is not involved in any transactions requiring disclosure under Item 404(a) of Regulation S-K, and has no family relationships with any of the company s directors or executive officers.

What agreements will DMIIU s new CFO enter into with the company?

In connection with his appointment, Saleem Elmasri is expected to enter into an Indemnity Agreement, a Letter Agreement, and a Registration Rights Agreement with the company on the same terms as the other directors and officers who executed similar agreements at the time of the company s initial public offering.